KR20090089135A - Composition having brain function and congnition enhancing activity comprising betula platy phylla sap - Google Patents
Composition having brain function and congnition enhancing activity comprising betula platy phylla sap Download PDFInfo
- Publication number
- KR20090089135A KR20090089135A KR1020080014524A KR20080014524A KR20090089135A KR 20090089135 A KR20090089135 A KR 20090089135A KR 1020080014524 A KR1020080014524 A KR 1020080014524A KR 20080014524 A KR20080014524 A KR 20080014524A KR 20090089135 A KR20090089135 A KR 20090089135A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- brain function
- sap
- memory
- phylla
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 230000003925 brain function Effects 0.000 title claims abstract description 18
- 235000001553 Betula platyphylla Nutrition 0.000 title abstract description 4
- 241001313086 Betula platyphylla Species 0.000 title abstract description 4
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000003920 cognitive function Effects 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 11
- 230000015654 memory Effects 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 208000000044 Amnesia Diseases 0.000 claims abstract description 5
- 206010012289 Dementia Diseases 0.000 claims abstract description 5
- 235000013361 beverage Nutrition 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 239000008187 granular material Substances 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 235000018185 Betula X alpestris Nutrition 0.000 claims description 29
- 235000018212 Betula X uliginosa Nutrition 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 14
- 206010027175 memory impairment Diseases 0.000 claims description 10
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 231100000863 loss of memory Toxicity 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000036541 health Effects 0.000 abstract description 2
- 208000031091 Amnestic disease Diseases 0.000 abstract 2
- 230000006986 amnesia Effects 0.000 abstract 2
- 239000006193 liquid solution Substances 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 9
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 9
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 9
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 9
- 229960002646 scopolamine Drugs 0.000 description 9
- 208000028698 Cognitive impairment Diseases 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001713 cholinergic effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000012440 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000011302 passive avoidance test Methods 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
본 발명은 뇌기능 및 인지 기능 개선 활성을 갖는 조성물에 관한 것으로서, 보다 상세하게는 자작나무 수액을 유효성분으로 함유하는 뇌기능 및 인지 기능 개선용 조성물에 관한 것이다.The present invention relates to a composition having a brain function and cognitive function improving activity, and more particularly to a composition for improving brain function and cognitive function containing birch sap as an active ingredient.
최근 노인성 치매가 퇴행성 중추신경계 질환으로 인정되고 그 환자의 수가 날로 증가됨에 따라 커다란 사회적인 문제로 대두되면서 이의 예방이나 개선, 치료에 대한 중요성이 새롭게 부각되고 있다. 노인성 질환 중에서 최근 사회 문제로 까지 대두되고 있는 치매 환자의 대부분이 알츠하이머씨 병 환자인 것으로 알려졌다. 알츠하이머씨(Alzheimer's disease) 병 환자는 콜린성, 아드레날린성, GABA성 및 글루타메이트성 신경 등 거의 모든 신경에 이상이 초래되며, 특히 콜린성 신경의 손실이 가장 심각한 것으로 알려져 있다. 이에 콜린성 신경의 이상을 회복시키거나 개선시키는 방향으로 알츠하이머씨 병의 치료제 개발 연구가 활발히 이루어지고 있다. As senile dementia has recently been recognized as a degenerative central nervous system disease and the number of patients has increased day by day, it has emerged as a big social problem, and the importance of its prevention, improvement and treatment is newly emerging. Alzheimer's disease is known to be the majority of dementia patients that have recently emerged as social problems. Alzheimer's disease patients suffer from abnormalities in almost all nerves, including cholinergic, adrenergic, GABA and glutamate nerves, and the loss of cholinergic nerves is known to be most serious. Therefore, researches for the development of Alzheimer's disease treatments have been actively conducted to restore or improve cholinergic disorders.
실험동물에 스코폴라민(scopolamine)을 투여하여 콜린성 신경계에 이상을 유발시켜 알츠하이머씨 병과 비슷한 상태를 인위적으로 조작할 수 있는 방법이 알려지면서 알츠하이머씨 병의 치료제 개발이 진일보하게 되었다(Flood, J. and Cherkin, A. Scopolamine effects on memory retention in mice, Behav. Neural. Biol. 45: 169-184(1986)). The development of a cure for Alzheimer's disease has been advanced as the method of artificially manipulating the condition similar to Alzheimer's disease by inducing abnormalities in the cholinergic nervous system by administering scopolamine to experimental animals (Flood, J.). and Cherkin, A. Scopolamine effects on memory retention in mice, Behav. Neural. Biol. 45: 169-184 (1986)).
흰쥐에 스코폴라민을 투여하면 콜린성 신경기능의 퇴행과 기억력 상실증이 나타나는 것은 물론, 습득력, 즉각적인 대응법, 활동기억(working memory)에 결함이 나타나는 등 알츠하이머씨 병 환자에게서 나타나는 증상과 유사한 증상이 나타난다(Smith, 1988; Giacobini, E. and Cuadra, G.(1994)). 이러한 증상은 콜린성 신경의 효능제인 아레콜린(arecoline) 및 옥소트레모린(oxotremorine)이나 아세틸콜린의 분해를 억제시킴으로써 세포 내의 아세틸콜린의 농도를 유지시키는 아세틸콜린에스테라제(acetylcholinesterase: AChE) 저해제인 피조스티그민(physostigmine) 등의 투여에 의하여 완화되었다. 실제로 AChE 저해제인 타크린(tacrine)은 임상에서 사용되고 있으나 간독성, 짧은 반감기 및 낮은 생체 내 이용률 등의 문제가 제기되고 있어 새로운 대체약물을 찾기 위한 연구가 활발히 진행되고 있다.The administration of scopolamine in rats is associated with symptoms similar to those in Alzheimer's disease, including degeneration of cholinergic neurons and loss of memory, as well as deficiencies in acquisition, immediate response, and working memory. Smith, 1988; Giacobini, E. and Cuadra, G. (1994)). These symptoms are Pizo, an acetylcholinesterase (AChE) inhibitor that maintains the concentration of acetylcholine in the cell by inhibiting the degradation of arecoline and oxotremorine or acetylcholine, which are agonists of cholinergic neurons. It was alleviated by the administration of physostigmine and the like. Indeed, tacrine, an AChE inhibitor, has been used in the clinic, but studies such as hepatotoxicity, short half-life, and low bioavailability have been raised.
본 발명자들은 새로운 뇌기능 및 인지 기능 개선 활성을 갖는 물질을 찾기 위하여 천연물을 대상으로 이의 활성을 검색하던 중 자작나무 수액이 유의성 있는 뇌기능 및 인지 기능 개선 활성을 갖고 있음을 확인하였다. The present inventors confirmed that birch sap has significant brain and cognitive function improving activity while searching for its activity in natural products to find a substance having new brain function and cognitive function improving activity.
본 발명의 자작나무(Betula Platy Phylla)는 자작나무과에 속하는 낙엽교목 으로서 강원도 이북의 높은 산에 많이 자라지만 일본의 북해도와 중국에도 분포한다. 수액은 흰빛이며 수평으로 벗겨지며, 소지는 암갈색으로 지점이 있다. 잎은 장지에서는 호생하며 단지에서는 2개씩 난다. 삼각상 난형으로 길이 5-7cm, 너비 4-6cm이며 예첨두이다. 넓은 설저 또는 아심장저이며 가장자리에 복거치가 있다. 거의 털이 없으나 잎뒷면 엽액에 갈모가 있는 경우도 있다.The birch (Betula Platy Phylla) of the present invention is a deciduous tree belonging to the birch family and grows in high mountains north of Gangwon-do but is also distributed in the North Sea of Japan and China. The sap is white, peeled horizontally, and the branch is dark brown with a spot. Leaves regenerate in the intestines and two in the complex. Triangular ovate, 5-7cm long, 4-6cm wide, with acute tip. It is a wide tongue or heart bottom and has a marginal value at the edge. There is almost no hair, but there are some hairs on the leaf fluid on the back of the leaf.
자작나무 수액은 글루코즈(glucose)와 프락토우즈(fructose)가 주요 성분이며, 칼륨, 나트륨, 마그네슘, 아연과 같은 무기질이 소량 함유되어 있으며, 아미노산(타우린, 글리신, 라이신, 알라닌, 트레오닌 등), 단백질 외에도 말릭산과 기타 알려지지 않은 성분과 같은 유기산으로 구성되어 있다. 수액은 달고, 맛있고, 상쾌한 맛을 갖고 있어 중국에서는 수년간 자작나무 수액을 모아서 음료로 사용해 왔고, 북유럽에서도 수액이 건강음료로 이용되고 있다. 자작나무 수액의 활성에 관한 연구는 부족한 실정이며 지금까지 자작나무 수액의 뇌기능 및 인지 기능과 관련된 연구는 수행된 바가 없었다. 본 발명에서는 자작나무 수액의 뇌기능 및 인지 기능 개선 활성을 나타냄을 놀랍게도 확인하여 본 발명을 완성하기에 이르렀다. The birch sap is composed mainly of glucose and fructose, and contains small amounts of minerals such as potassium, sodium, magnesium, and zinc, and amino acids (taurine, glycine, lysine, alanine, threonine, etc.), In addition to protein, it consists of organic acids such as malic acid and other unknown constituents. The sap has a sweet, delicious and refreshing taste. In China, birch sap has been collected and used for many years in China, and sap is used as a health drink in Northern Europe. The research on the activity of birch sap is insufficient, and so far, no research on the brain function and cognitive function of birch sap has been conducted. In the present invention, it was surprisingly confirmed that the sap of the birch sap to improve brain function and cognitive function to complete the present invention.
본 발명은 유효성분으로서 자작나무 수액을 단독으로 포함하거나, 약제학적 또는 식품학적으로 허용되는 부형제와 함께 포함하는 뇌기능 및 인지 기능 개선용 조성물을 제공한다. The present invention provides a composition for improving brain function and cognitive function comprising birch sap alone as an active ingredient, or in combination with a pharmaceutically or food-acceptable excipient.
본 발명은 또한 자작나무 수액을 포함하는 조성물을 함유하는 뇌기능 및 인지 기능 개선 효과를 나타내는 식품첨가물, 건강보조식품, 또는 약제학적 조성물을 제공한다. 상기 건강보조식품, 또는 약제학적 조성물은 정제, 캅셀제, 분말제, 과립제, 액상제 및 음료로 구성된 군으로부터 선택되는 것이 바람직하다.The present invention also provides a food additive, dietary supplement, or a pharmaceutical composition exhibiting a brain and cognitive function improving effect containing a composition comprising birch sap. The dietary supplement or pharmaceutical composition is preferably selected from the group consisting of tablets, capsules, powders, granules, liquids and beverages.
본 발명은 유효성분으로서 자작나무 수액을 포함하는 뇌기능 및 인지 기능 개선용 조성물을 제공한다. The present invention provides a composition for improving brain function and cognitive function, including birch sap as an active ingredient.
본 발명의 자작나무 수액은 자작나무로부터 통상의 채취 방법을 통해 채취하거나, 시판되는 자작나무 수액, 예컨대, SK 건설(주)의 자작나무 수액(상품명: 행복한 산책)을 구입하여 이를 사용할 수 있다. 또한 상기 채취된 수액을 채취과정상의 변화를 줄이기 위해, 이를 여과등의 처리수단으로 가공한 여과물, 또는 수액을 농축하거나, 동결건조한 분말등도 본 발명의 자작나무 수액으로 사용할 수 있음은 명백하다. The birch sap of the present invention can be collected from a birch through a conventional harvesting method, or a commercially available birch sap, for example, can be used by purchasing a birch sap (trade name: Happy Walk) of SK Construction. In addition, in order to reduce the change in the collected process of the collected sap, it is obvious that the filtrate processed by the processing means such as filtration, or the sap concentrated or lyophilized powder can also be used as the birch sap of the present invention. .
본 발명에 있어서, 상기 자작나무 수액은 하기 실험예와 같이 우수한 뇌기능 및 인지 기능 개선 활성을 나타내었다. In the present invention, the birch sap showed excellent brain function and cognitive function improving activity as in the following experimental example.
본 발명의 조성물은 뇌기능 및/또는 인지 기능 개선 효과를 나타내며, 기억력 상실, 기억력의 손상, 특히 습득력의 결함 및/또는 활동기억 상실과 관련된 기억력의 손상, 치매, 건망증, 알츠하이머씨병 등의 예방 및 치료용 조성물로써 사용할 수 있다. The composition of the present invention exhibits an effect of improving brain function and / or cognitive function, prevents memory loss, memory impairment, in particular memory impairment associated with deficiency of acquisition and / or loss of activity memory, dementia, forgetfulness, Alzheimer's disease, and the like. It can be used as a therapeutic composition.
본 발명의 조성물은 약제학적 또는 식품학적 분야에서 공지의 방법의 의해 제제화될 수 있고, 그 자체 또는 약제학적으로 허용되는 담체, 부형제 등과 혼합하여 약제학적 또는 식품학적으로 통상으로 허용되는 제제, 예를 들면 액제, 시럽제, 캡슐제 등으로 제제화될 수 있으며, 이들은 경구 또는 비경구로 투여될 수 있다.The compositions of the present invention may be formulated by methods known in the pharmaceutical or food arts, and may be used alone or in admixture with pharmaceutically acceptable carriers, excipients, etc. For example, it may be formulated as a liquid, syrup, capsule, and the like, which may be administered orally or parenterally.
상기 본 발명의 조성물을 포함하는 액제, 캡슐제, 음료 등은 건강보조식품으로 사용될 수 있으며, 본 발명에서 사용된, 용어 "건강보조식품"이라 함은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀제, 분말제, 과립제, 액상제, 환제 등의 형태로 제조 가공한 건강식품 또는 음료, 요구르트, 치즈 등의 기능성 식품을 말한다.Liquids, capsules, beverages, etc. comprising the composition of the present invention can be used as a dietary supplement, the term "health supplement" used in the present invention is used as a raw material or ingredient having a useful functionality to the human body Refers to functional foods such as health foods or beverages, yogurt, cheese, etc. manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like.
본 발명의 조성물은 체내에서 활성성분의 흡수도, 배설속도, 환자의 연령 및 체중, 성별 및 상태, 치료할 질병의 중증정도 등에 따라 적절히 선택되나, 일반적으로 자작나무 수액을 적량, 예컨대, 100∼200ml 용량으로 1일 수회 음용하거나, 이의 건조 분말을 성인에게 1일 0.01∼500mg/kg, 바람직하게는 0.1∼200mg/kg으로 투여하는 것이 바람직하다. 이렇게 제형화된 단위투여형 제제는 필요에 따라 일정시간 간격으로 수회 투여할 수 있다.The composition of the present invention is appropriately selected depending on the absorption of the active ingredient in the body, the rate of excretion, the age and weight of the patient, the sex and condition, the severity of the disease to be treated, etc. In general, a birch sap in a suitable amount, for example, 100 to 200ml It is preferable to drink several times a day at a dose, or to administer the dry powder thereof to an adult at 0.01 to 500 mg / kg, preferably 0.1 to 200 mg / kg per day. The unit dosage form so formulated may be administered several times at regular time intervals as needed.
이하, 본 발명을 하기 실시예를 통하여 더욱 상세히 설명한다. 이들 실시예는 본 발명의 예시 목적을 위한 것이며, 본 발명의 보호범위를 제한하고자 하는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. These examples are for illustrative purposes of the present invention and are not intended to limit the protection scope of the present invention.
실시예Example 1 One : 시험물질: Test substance
시판 자작나무 수액(SK 건설(주), 상품명: 행복한 산책)을 구입하여, 이를 감압농축 및 동결건조한 후, 분말화하여 하기 실험예에 사용하였다. Commercial birch sap (SK Construction Co., Ltd., trade name: Happy Walk) was purchased, concentrated under reduced pressure and lyophilized, and then powdered and used in the following experimental example.
실험예Experimental Example 1 One
1. 실험 방법1. Experiment Method
1) 실험동물1) Experimental Animal
서울대학교 실험동물 사육실에서 충분한 물과 사료로 사육한 25-30g의 ICR계 마우스(male)를 공급받아 1주일 동안 실험실 환경에 적응시킨 후 실험에 사용하였다.Seoul National University experimental animal breeding room was supplied with 25-30g of ICR male (male) reared with sufficient water and feed was used for the experiment after being adapted to the laboratory environment for one week.
2) 수동적 회피반응 측정(Passive avoidance test)2) Passive avoidance test
하단에 두께 3mm의 스테인레스 막대가 0.5cm 간격으로 설치된 회피상자(40 X 20 X 20 cm)를 밝은 방과 어두운 방으로 나누고 밝은 방에 넣은 마우스가 어두운 방으로 들어갔을 때 스테인레스 막대를 통하여 0.2 mA/10g 체중의 전기자극을 주는 훈련을 시켰다. 24시간 후 동일한 시험을 실시하여 마우스가 밝은 방에 머무르는 시간(Step through latency)을 측정하여 전일의 훈련을 기억하는 지표로 하여 실시예 1의 투여군, 콘트롤군 및 대조군 투여군을 비교하였다. 스코폴라민을 생리식염 수에 녹여 1.5mg/kg의 용액을 제조하여 훈련시행 30분전에 피하주사하여 기억력 및 인지기능 손상을 유발시키며, 스코폴라민 투여 1시간 30분 전에 실시예 1의 자작나무 수액을 생리식염수에 녹여 30mg/ml, 50mg/ml, 100mg/ml으로 각각 구강투여 하여 스코폴라민에 의해 유도된 기억력 및 인지기능 손상에 어떤 영향을 미치는지를 관찰하였다.Split the evacuation box (40 X 20
그 결과를 도 1에 나타내었다. 도 1에 있어서, "콘트롤"은 스코폴라민과 자작나무 수액을 모두 먹이지 않은 정상군에 해당하여, "스코폴라민"은 대조군으로서, 실시예 1에서 제조한 자작나무 수액을 처리하지 않고 오직 스코폴라민으로만 처리하여 기억력 및 인지기능 손상을 유발한 군에 해당한다.The results are shown in FIG. In Figure 1, "control" corresponds to the normal group not fed both scopolamine and birch sap, "scopolamine" as a control, without treating the birch sap prepared in Example 1 It is the group that treated with only polyamine and caused memory and cognitive impairment.
도 1에서 나타난 바와 같이, 스코폴라민에 의하여 유도된 기억력 및 인지기능 손상을 유도한 마우스의 수동적 회피반응 테스트에서 자작나무 수액을 30mg/ml, 50mg/ml, 100mg/ml로 섭취시켰을 때 스텝 쓰루 레이턴시(Step through latency)가 농도 의존적으로 각각 35.5%, 53.3%, 76.4%으로 회복율이 증가하였다. 이와 같이, 자작나무 수액이 기억력 및 인지기능 손상에 있어 유의성 있는 효과를 나타냄을 알 수 있다. As shown in Fig. 1, step through when birch sap was ingested at 30 mg / ml, 50 mg / ml, and 100 mg / ml in a passive avoidance reaction test of mice induced memory and cognitive impairment induced by scopolamine. The recovery rate increased to 35.5%, 53.3%, and 76.4%, depending on the concentration. Thus, it can be seen that birch sap has a significant effect on memory and cognitive impairment.
조성물 Composition 실시예Example
조성물예Composition example 1. 캡슐제의 제조 1. Preparation of Capsule
실시예 1의 자작나무 수액 200mg200 mg of birch sap of Example 1
유당 100mgLactose 100mg
전분 93mgStarch 93mg
탈크 2mgTalc 2mg
스테아린산 마그네슘 적량Magnesium stearate proper amount
상기의 성분을 혼합하고 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충진하여 캡슐제를 제조한다.The capsules are prepared by mixing the above components and filling gelatin capsules according to a conventional method for preparing capsules.
조성물예Composition example 2. 캡슐제의 제조 2. Preparation of Capsule
실시예 1의 자작나무 수액 100mg100 mg of birch sap of Example 1
유당 100mgLactose 100mg
전분 93mgStarch 93mg
탈크 2mgTalc 2mg
스테아린산 마그네슘 적량Magnesium stearate proper amount
상기의 성분을 혼합하고 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충진하여 캡슐제를 제조한다.The capsules are prepared by mixing the above components and filling gelatin capsules according to a conventional method for preparing capsules.
도 1은 본 발명의 자작나무 수액에 대한 기억력 회복 효과를 나타낸 도면이다. 1 is a view showing the memory recovery effect on the birch sap of the present invention.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080014524A KR100950255B1 (en) | 2008-02-18 | 2008-02-18 | Composition having congnition enhancing activity comprising Betula Platy Phylla sap |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080014524A KR100950255B1 (en) | 2008-02-18 | 2008-02-18 | Composition having congnition enhancing activity comprising Betula Platy Phylla sap |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090089135A true KR20090089135A (en) | 2009-08-21 |
KR100950255B1 KR100950255B1 (en) | 2010-03-31 |
Family
ID=41207485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080014524A KR100950255B1 (en) | 2008-02-18 | 2008-02-18 | Composition having congnition enhancing activity comprising Betula Platy Phylla sap |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100950255B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200112541A (en) | 2019-03-22 | 2020-10-05 | 이학봉 | Antiobesity composition comprising birch extract |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06311868A (en) * | 1993-04-28 | 1994-11-08 | Isukura Sangyo Kk | Food liquid composed mainly of white birch sap |
US20060014704A1 (en) | 2004-07-16 | 2006-01-19 | Landry Donald W | Compounds and their preparation for the treatment of Alzheimer's disease by inhibiting beta-amyloid peptide production |
JP5068952B2 (en) | 2006-02-16 | 2012-11-07 | 株式会社コーセー | Involucrin production promoter |
-
2008
- 2008-02-18 KR KR1020080014524A patent/KR100950255B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR100950255B1 (en) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8492442B2 (en) | Medicinal composition, food or drink having effect of enhancing parasympathetic nervous activity | |
CN102438642A (en) | Composition comprising green tea extract | |
US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
TW201828955A (en) | Anti-fatigue composition used for increasing endurance performance | |
EP2990048B1 (en) | Nitric oxide concentration elevating agent | |
WO2007007993A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea l. var. edulis extract | |
KR20110005144A (en) | Pharmaceutical composition and health-food composition containing ginseng extracts having neuroprotective effects | |
KR20160107420A (en) | A composition comprising ginsenoside f2 for preventing or treating non-alcoholic liver disease | |
JP2014237715A (en) | Agent for alleviating alcoholic fatigue | |
WO2005087022A1 (en) | Food composition having antistress effect | |
KR100950255B1 (en) | Composition having congnition enhancing activity comprising Betula Platy Phylla sap | |
KR20140077483A (en) | Composition for preventing or treating the brain ischemia disease containing extract of glehnia littoralis | |
KR20160100279A (en) | Anti-cancer composition containing erythronium japonicum extract | |
US20100074975A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract | |
KR20120113924A (en) | Composition comprising extract of daphne genkwa as active ingradient | |
KR101870280B1 (en) | A composition for removing hangover comprising an extract of Cinnamomum cassia Presl and cinnamomi petiole | |
JPH07228539A (en) | Extrct from leaf lagerstroemia speciosa and antidiabetic agent | |
KR101852583B1 (en) | Composition for preventing the ischemic stroke disease containing populus tomentiglandulosa extract | |
KR20210146590A (en) | Pharmaceutical composition for preventing or treating cancer comprising belamcandae rhizoma extract as an active ingredient | |
KR20110004691A (en) | Pharmaceutical composition and health-food composition containing extract from rhus chinensis having improvement-effect of brain-fuction | |
KR101780718B1 (en) | Pharmaceutical composition for preventing or treating diabetes mellitus comprising seed extract of platycodon | |
JP2007045750A (en) | Anti-fatigue agent | |
KR100950254B1 (en) | Composition having congnition enhancing activity comprising Betula Platy Phylla extract | |
KR20130065117A (en) | Composition comprising water extracts from tremella foliacea fr. for treating or preventing obesity | |
KR20130065127A (en) | Composition comprising alcohol extracts from oligoporus tephroleucus for treating or preventing hyperlipidemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130315 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140312 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160318 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170104 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190325 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20200130 Year of fee payment: 11 |